These are different medicines and are not automatically interchangeable, so only your provider can decide which one is right for you
It is used to treat children with growth hormone deficiency, adult GH deficiency, catabolic stats, and obesity
Pintea A, Manea A, Pintea C, et al
As interest in advanced research peptides continues to grow, Retatrutide has become one of the most talked-about compounds in peptide research discussions
Scientific and Official Sources PubChem: BPC-157 identity, synonyms, molecular formula and mass Sikiric and colleagues: early published BPC-157 research ClinicalTrials.gov: PCO-02 BPC-157 safety and pharmacokinetics study Lee and colleagues: two-participant BPC-157 intravenous pilot study McGuire and colleagues: narrative review of BPC-157 evidence and risk World Anti-Doping Agency: 2026 Prohibited List MHRA: Borderline products and how to tell if a product is a medicine Human Medicines Regulations 2012: Regulation 279 United States FDA: safety risks associated with certain bulk substances, including BPC-157 United States FDA: BPC-157-related bulk-substance briefing document CAP Code Section 12: Medicines and health-related products Health and Safety Executive: UK REACH Health and Safety Executive: Safety Data Sheets and COSHH Health and Safety Executive: COSHH risk assessment Cox and colleagues: identification and analytical detection of BPC-157 in confiscated material
Clinical trials show that GLP-1 therapy users who lose 515% of body weight often see systolic blood pressure drop by 38 mmHg within the first 6 months
